Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The FDA has approved Novo Nordisk A/S's (NYSE: NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes.  Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2.

Why Novo Nordisk Shares Are Trading Higher Today

Novo Nordisk's Ozempic drug gets FDA OK for 2 mg dose to treat Type-2 Diabetes

Dell Technologies

These stocks also make for promising long-term growth investments.

Got $5,000? These 2 Dividend Stocks Are Bargain Buys

Bagsværd, De n mark, 3 March 202 2 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.

Highlights to be presented at Novo Nordisk's Capital Markets Day 2022

Bagsværd, Denmark, 2 8 February 20 22 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S.

Election of employee representatives to the Board of Directors of Novo Nordisk A/S

Trading in Novo Nordisk shares by board members, executives and ass ociated persons on 8 February 202 2

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2022

Trading in Novo Nordisk shares by board members, executives and ass ociated persons on 4 February 202 2

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 4 February 2022

Bagsværd, Denmark, 4 February 202 2 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 2-4 February 2022

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call Transcript

Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Danish drug developer Novo Nordisk posted on Wednesday fourth quarter operating profit that was below expectations, and said it expected to generate sales growth in local currencies of between 6% and 10% in 2022.

Novo Nordisk posts Q4 operating profit below estimates

Financial report for the period 1 January 2021 to 31 December 2021

Novo Nordisk's sales increased by 11% in Danish kroner and by 14% at constant exchange rates to DKK 140.8 billion in 2021

ABB Ltd.

Ashtead Group PLC

ASML Hld

Experian PLC

Nestle SA

Roche Holding AG

Sage Group PLC/The

Sanofi

Unilever

A recent pullback in the global equities market has opened the door for investors to buy some of the top dividend-paying European stocks at a discount.

The 10 Best European Stocks for 2022 and Beyond

NVO has increased their market share more rapidly than the overall market growth for diabetes treatment.

Novo Nordisk: Continued Dominance In Diabetes Care

Bagsværd , De n mark, 14 January 202 2 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs.

Novo Nordisk announces settlement of securities lawsuit in Denmark

Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug Wegovy, reported BioProcess International reported. An FDA inspection of the CDMO's filling site in Brussels yielded a Form 483, the publication said, calling it a "recent" inspection.

FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report

Alphabet

Home Depot

NVIDIA

Wells Fargo

These were the most important forces driving the stock market last year.

These 5 Stocks Moved the Market in 2021

Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had temporarily halted deliveries and manufacturing after issues relating to good manufacturing practices. Consequently, fewer new patients will start treatment with Wegovy in 1H 2022.

Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades

Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.

Novo Nordisk shares slump on U.S. supply challenges for obesity drug

Bagsværd , De n mark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy ® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices.

Novo Nordisk announces supply challenges for Wegovy® in the US

NEW ORLEANS, Dec. 14, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA

EUGENE, Ore.--(BUSINESS WIRE)-- #BehavioralHealth--Ksana Health, a digital behavioral health company, today announced its selection by Novo Nordisk's Global Prevention Accelerator.

Digital Behavioral Health Innovator Ksana Health Joins Novo Nordisk's Global Prevention Accelerator

Bagsværd , De n mark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk's insulin were included in the tender except for Ryzodeg® and Xultophy®.

Novo Nordisk announces impact from Volume Based Procurement for insulin in China

Dicerna Pharmaceuticals

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

News for Novo Nordisk Stock (NVO)